Using gene-edited tumor cells to improve cancer treatment for brain tumors
Gene Edited and Engineered Tumor Cell Therapeutics for Cancer
This study is exploring a new way to treat aggressive brain cancer by using specially modified cancer cells to help your immune system fight the tumors better, and if it works, it could lead to a promising new therapy for patients like you.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Brigham and Women's Hospital NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project ID | NIH-11055286 on NIH RePORTER |
What this research studies
This research focuses on developing a novel cancer therapy using gene-edited tumor cells to enhance the immune response against glioblastomas, a type of aggressive brain cancer. The approach involves modifying cancer cells with CRISPR technology to express proteins that stimulate the immune system, potentially leading to better tumor targeting and destruction. By testing these engineered cells in mouse models that closely resemble human conditions, the researchers aim to understand how to effectively activate the immune system against these tumors. Patients may benefit from this innovative therapy if it proves effective in clinical settings.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with glioblastoma who have limited treatment options due to the aggressive nature of their tumors.
Not a fit: Patients with non-brain cancers or those whose tumors are not glioblastomas may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for patients with glioblastomas, potentially improving survival rates and quality of life.
How similar studies have performed: Other research has shown promise in using gene editing and immunotherapy for cancer treatment, indicating potential for success in this novel approach.
Where this research is happening
Boston, United States
- Brigham and Women's Hospital — Boston, United States (Active)
Researchers
- Principal investigator: Shah, Khalid a — Brigham and Women's Hospital
- Study coordinator: Shah, Khalid a
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.